tetano
Editor, Senior Moderator
J Clin Med
. 2023 Nov 10;12(22):7028.
doi: 10.3390/jcm12227028. Immediate Postoperative COVID-19 Infection after Lung Transplantation: A Systematic Review and Case Series
Jack K Donohue[SUP] 1 [/SUP], Eric J Hyzny[SUP] 1 [/SUP], Sarah Clifford[SUP] 1 [/SUP], Ernest G Chan[SUP] 1 [/SUP], Jenalee Nicole Coster[SUP] 1 [/SUP], Masashi Furukawa[SUP] 1 [/SUP], Pablo G Sanchez[SUP] 1 [/SUP]
Affiliations
Background: With new variants challenging the effectiveness of preventive measures, we are beginning to recognize the reality that COVID-19 will continue to pose an endemic threat. The manifestations of COVID-19 in lung transplant recipients during index admission are poorly understood with very few cases reported in recent lung transplant recipients. Optimal management of immunosuppression and antiviral therapy in recent transplant recipients is challenging.
Methods: We performed a retrospective analysis identifying lung transplant recipients at our institution who contracted COVID-19 in the immediate postoperative period (within index admission). In addition, we performed a systematic review from January 2020 to August 2023 identifying all publications on the PUBMED database regarding COVID-19 infection in lung transplant recipients during index admission.
Results: We report four cases of COVID-19 pneumonia in lung transplant recipients in the immediate postoperative period and we describe the clinical course, treatment options, and immunosuppression changes to manage this unique clinical problem. All patients made a full recovery and were eventually discharged home. Within our review of the literature, the most prevalent presenting symptoms were cough, dyspnea, and fatigue. Six (75%) patients decreased or held their antimetabolite. The two most common treatments were monoclonal antibodies (38%) and remdesivir (63%).
Conclusion: Although previous literature demonstrates that COVID-19 can be deadly in recent lung transplant recipients, rapid treatment with anti-viral therapy/immunotherapy, deescalating immunosuppression, and treatment of respiratory decompensation with Decadron was effective in our patients.
Keywords: COVID-19; coronavirus; immunosuppression; lung transplantation.
. 2023 Nov 10;12(22):7028.
doi: 10.3390/jcm12227028. Immediate Postoperative COVID-19 Infection after Lung Transplantation: A Systematic Review and Case Series
Jack K Donohue[SUP] 1 [/SUP], Eric J Hyzny[SUP] 1 [/SUP], Sarah Clifford[SUP] 1 [/SUP], Ernest G Chan[SUP] 1 [/SUP], Jenalee Nicole Coster[SUP] 1 [/SUP], Masashi Furukawa[SUP] 1 [/SUP], Pablo G Sanchez[SUP] 1 [/SUP]
Affiliations
- PMID: 38002643
- PMCID: PMC10671990
- DOI: 10.3390/jcm12227028
Background: With new variants challenging the effectiveness of preventive measures, we are beginning to recognize the reality that COVID-19 will continue to pose an endemic threat. The manifestations of COVID-19 in lung transplant recipients during index admission are poorly understood with very few cases reported in recent lung transplant recipients. Optimal management of immunosuppression and antiviral therapy in recent transplant recipients is challenging.
Methods: We performed a retrospective analysis identifying lung transplant recipients at our institution who contracted COVID-19 in the immediate postoperative period (within index admission). In addition, we performed a systematic review from January 2020 to August 2023 identifying all publications on the PUBMED database regarding COVID-19 infection in lung transplant recipients during index admission.
Results: We report four cases of COVID-19 pneumonia in lung transplant recipients in the immediate postoperative period and we describe the clinical course, treatment options, and immunosuppression changes to manage this unique clinical problem. All patients made a full recovery and were eventually discharged home. Within our review of the literature, the most prevalent presenting symptoms were cough, dyspnea, and fatigue. Six (75%) patients decreased or held their antimetabolite. The two most common treatments were monoclonal antibodies (38%) and remdesivir (63%).
Conclusion: Although previous literature demonstrates that COVID-19 can be deadly in recent lung transplant recipients, rapid treatment with anti-viral therapy/immunotherapy, deescalating immunosuppression, and treatment of respiratory decompensation with Decadron was effective in our patients.
Keywords: COVID-19; coronavirus; immunosuppression; lung transplantation.